Inspirata Inc. has acquired GE company Caradigm in an effort to speed up development of its Cancer Information Data Trust (CIDT).

The cancer informatics and digital pathology workflow provider plans to leverage the capabilities of the Caradigm Intelligence Platform (CIP) to assist its CIDT in providing new insights on key trends in oncology for clinicians, researchers, drug discovery, and cancer center operations.

“Inspirata’s Cancer Information Data Trust (CIDT) is a big data platform for oncology that provides cancer centers and hospitals with insights to clinical care and research activities, enabling precision intervention, cost reduction and optimized patient outcomes,” Trevor Heritage, SVP Cancer Informatics at Inspirata, told HCB News. “The Caradigm Intelligence Platform’s core capability of integrating highly dimensional, multi-omics and imaging data within increasingly complex clinical and translational workflows, significantly reduces Inspirata’s time to market with the comprehensive CIDT platform, while also broadening the scope of CIDT beyond cancer to other areas of clinical care.”

Initially developed in 2012 as a joint venture between Microsoft and GE, CIP is an open and flexible platform designed to provide information at the point of care by drawing data from clinical, social, operational and financial sources including EHRs, billing systems, payers, claims, pharmacy systems, labs, and HIEs. GE acquired the full stake of Caradigm in 2016.

The current acquisition will oversee the integration of Inspirata’s NLP capabilities with the platform for processing unstructured data sources, which contain more than 70 percent of clinical data.

This will enable CIP to publish that information using a semantic data layer and dynamic schemas for a variety of applications and documentation, including pathology reports, treatment plans, physician notes, discharge summaries, and patient reported surveys.

In addition, Inspirata’s AI tools will be added to derive clinically actionable insights from the information to support patient engagement and workflow for clinical decision-making, precision medicine, healthcare operations, quality improvement, clinical trials, and research programs.

It also plans to use Caradigm’s suite of population health solutions to provide effective coordination and engagement capabilities for improving patient experiences, enhancing population health, increasing positive outcomes and reducing the per capita cost of healthcare.

Both Caradigm’s CIP and population health management solutions will be used to equip these abilities and ones that allow for data control and healthcare analytics to a range of players in healthcare, including large integrated delivery networks, accountable care organizations, clinically integrated networks, academic medical centers and community hospital networks.

“Inspirata’s focus in oncology brings an additional dimension to the Caradigm CIP platform at a time when healthcare organizations are highly focused on expanding their oncology service lines and revenue, optimizing cancer care and patient outcomes, while managing complexity and costs,” Heritage said. “CIP Visual Analytics also provides an analytics and business intelligence environment providing deep insights into healthcare data.”

With the exception of Neal Singh, who stepped down as CEO and president of Caradigm, all employees and leadership teams have transitioned over to Inspirata.

Financial details were not disclosed.